Chemo Stability Chart - AtoK PDF

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART
DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special
(Storage Prior to Use, With: Stability Precautions/Notes
Manufacturer,
Preservative Status)
AGS-16C3F
1 1 1
30 mg 5.1 mL SWI 6 mg/mL discard unused ≥ 0.3 mg/mL complete - unopened vials
1
(Astellas) portion administration within may be kept at RT
2,3
(F)(PFL) swirl gently; do NOT 100 mL D5W 6 h RT of for up to 4h prior to
1 1 1
do not shake shake (PFL) reconstitution use if protected from
1 1
no preservative mix by gentle light
1
allow foam to clear inversion **(PFL)
1
before proceeding
record time of
reconstitution
Aldesleukin
4,5 4 4 4
22 million units 1.2 mL SWI 18 million unit/mL 48 h F 50 mL D5W 48 h F - do not use in-line
4,5 4,5
(1.3 mg) (1.1 mg/mL) filter
4
(Novartis) direct diluent against 30 – 70 mcg/mL - avoid bacteriostatic
(F)(PFL) side of vial during water for injection or
4 4
no preservative reconstitution Less than 30 mcg/mL: NS due to increased
4
dilute in D5W aggregation
4
do NOT shake containing human
5
albumin 0.1%
6,7 7
SC syringe 14 d F
**(PFL)
BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 1/49

Activation Date: 2 March 2006
Revised Date: 19 July 2019
Manufacturer,
Alemtuzumab
9 10 11
30 mg/mL N/A filter NOT required discard unused SC syringe discard at the end of - do NOT shake
8 9
(Genzyme/Bayer) portion the day F, RT
9
(F)(PFL) 30 mg/mL
9 9
do not shake 100 mL NS, D5W 8 h F, RT
9
no preservative
11
**(PFL)
Amsacrine
12 12 12 12-14
75 mg/1.5 mL glass syringes 5 mg/mL 24 h RT 500 mL D5W 7 d F, 48 h RT - contains DMA***
(Erfa Canada) preferred during
12
(RT) reconstitution; (**PFL) (plastic or glass
12 12
no preservative max. time in plastic container)
12
syringe : 15 min
13.5 mL supplied
diluent (L-lactic
1
acid)
transfer 1.5mL from

ampoule into the
12
diluent vial
Arsenic
15 15
10 mg/10 mL N/A 1 mg/mL discard unused 100-250 mL NS, 24 h RT, 48 h F
15 15
(Lundbeck/Teva) portion D5W
(RT) (use filter needle to
15
no preservative withdraw from
ampoule)

Manufacturer,
Asparaginase
16 16
(asparaginase E. coli) 4 mL SWI 2500 units/mL 72 h F, 3 h RT syringe complete
10,000 units administration within
16
(CGF/EUSA) do NOT shake; 72 h F, 3 h RT
16
(F) rotate gently
16
no preservative
50-250 mL NS or complete
17
D5W administration within
16,18
3 h RT
Erwinia asparaginase
19 19 19
(asparaginase Erwinia 1-2 mL NS 10 000-5000 15 min RT glass or 4 h RT - contact with the
chrysanthemi) units/mL polypropylene rubber stopper may
19
10,000 units do NOT shake; mix syringe denature the
(CGF/EUSA) gently to minimize (use 5 micron filter reconstituted drug,
(F) bubbles and contact needle to withdraw creating filaments of
19 19 20 19
no preservative with stopper from vial) insoluble material
- discard if
particulate matter is
20
present
- do not use sterile
water for
reconstitution as the
resulting product is
19
not isotonic
PEG-asparaginase -
see pegaspargase in
L-Z chart
(pegylated
asparaginase E. coli)

Manufacturer,
Atezolizumab
21 22
1200 mg/20 mL N/A 60 mg/mL discard unused 250 mL NS only complete - discard vial if
21
(Hoffman-La Roche) portion administration within cloudy, discoloured
21
(F)(PFL) mix by slow 24 h F, 8 h RT (should be clear to
22
do not shake inversion pale yellow), or
21 22
no preservative visible particles
22
- do NOT shake
Avelumab
23 23
200 mg/10 mL N/A 20 mg/mL discard unused 250 mL NS, complete - do NOT shake
18
(EMD) portion 0.45% sodium administration within - use 0.2 micron in-
23 23
(F)(PFL) chloride 24 h F, 8 h RT line filter to
23 23
no preservative if refrigerated, administer
bring vial to RT mix by gentle if refrigerated, bring
23 23
prior to use inversion bag to RT prior to
23
administration

Manufacturer,
azaCITIDine
24 24 24
100 mg 4 mL SWI 25 mg/mL 45 min RT, 8 h SC syringe 45 min RT (including - discard if contains
24 24
(Celgene) F preparation time), 8 h large particles
24 24
(RT) shake vigorously F - re-suspend syringe
24
no preservative contents before
record time of refrigerate syringe injection by
reconstitution immediately after vigorously rolling
preparation if not to syringe between
24
be used within 45 palms
minutes of -if cold diluent
25
reconstitution reconstitution is used
to extend stability,
minimize exposure to
24 26,27 26,27
cold diluent 25 mg/mL 22 h F 22 h F RT; ensure proper
reconstitution: refrigeration of
4 mL SWI at 2- diluent, reconstituted
26,27
8°C vial, and final
product
Refrigerated
24
syringes :
 allow up to 30 min
prior to
administration to
reach a
temperature of ~20-
25°C
 discard syringe if
time elapsed at RT
is greater than 30
min

Manufacturer,
azaCITIDine
28 28 28 28
100 mg 4 mL SWI 25 mg/mL 45 min RT, 8 h SC syringe 45 min RT (including - do not filter
28
(Dr. Reddy‘s) F preparation time), 8 h - discard if contains
28 28 28
(RT) shake vigorously F large particles
28
no preservative - re-suspend syringe
refrigerate syringe contents before
immediately after injection by
preparation if not to vigorously rolling
be used within 45 syringe between
28
minutes of palms
28
reconstitution
Refrigerated
28
syringes :
 allow up to 30 min
prior to
administration to
reach a
temperature of
approximately 20-
25°C
 discard syringe if
time elapsed at RT
is greater than 30
min

Manufacturer,
BCG
8 29
(Tice substrain) 1 mL preservative- 1 to 8×10 2hF transfer from vial to use within 2 h F of - auxiliary info:
29 29 29,30 30
intravesical free NS CFU/vial 60 mL syringe, rinse reconstitution biohazard
8 29 29
50 mg = 1 to 8 x 10 **(PFL) vial with another 1 mL - do NOT filter
29 29
CFU allow to stand for a NS; add rinse to **(PFL) - do NOT shake
(Merck Canada) few minutes, then same 60 mL syringe
(F)(PFL) gently swirl to and qs to 50 mL with
29 29 29
no preservative suspend NS
record time of if a closed system

reconstitution transfer device is
used:
transfer from vial to
60 mL syringe and qs
to 50 mL with NS; do
29
NOT rinse vial
BCG
8 31
(Tice substrain) 1 mL preservative 1 to 8×10 2hF transfer from vial to use within 2 h F of - auxiliary info:
31 31 30,31 30
intravesical free NS CFU/vial 60 mL syringe and qs reconstitution biohazard
8 31 31 31
50 mg = 1 to 8 x 10 (PFL to 50 mL with NS - do NOT filter
31 31
CFU allow to stand for a **(PFL) - do NOT shake
(Merck USA) few minutes, then
(F)(PFL) gently swirl to
31 31
no preservative suspend
record time of
reconstitution

Manufacturer,
BCG
32 32
intravesical do NOT shake; roll 10.5 ± 8.7×108 2 h F, RT 50 mL NS 2 h F or RT after - auxiliary info:
32 32 18
81 mg to reconstitute CFU/vial reconstitution biohazard
(Sanofi Pasteur) (Connaught
32 32
(F)(PFL) 3 mL supplied strain) **(PFL)
32 32
preservative diluent
record time of
reconstitution
Belinostat
33 33 33 33
500 mg 9 mL SWI 50 mg/mL 12 h RT 250 mL NS complete - use 0.22 micron
(Spectrum) administration within inline filter to
33 33
(RT) 36 h RT administer
33
no preservative
Bendamustine
34 34
25 mg 25 mg vial: 5 mg/mL 30 minutes 0.2-0.6 mg/mL NS, complete
34 34
100 mg add 5 mL SWI D2.5-½NS administration within
35
(Lundbeck/Teva) 24 h F, 3 h RT
34
(RT,F)(PFL) 100 mg vial: 250* - 500 mL
34 34
no preservative add 20 mL SW
shake well;
dissolves completely
34
in 5 minutes

Manufacturer,
Bevacizumab
36 37 36-38 36
100 mg/4 mL N/A 25 mg/mL discard unused 1.4-16.5 mg/mL 48 h F, RT - do NOT shake
36
400 mg/16 mL portion
(Roche) 100-250 mL NS
36,37
(F)(PFL) only
do not shake
36
no preservative
Bleomycin
39 39 39 39
15 units 6 mL* NS 2.5 units/mL 48 h F 50 mL* NS 24 h RT
(NB: dose in units only)
(Fresenius Kabi)
(F)(PFL)
39
no preservative
Bleomycin
40 40 41
15 units 6 mL* NS, SWI 2.5 units/mL 48 h F, 24 h RT 50 mL* NS{14216}} 4 h RT
(NB: dose in units only)
(Pfizer/Hospira)
(F)(PFL)
40
no preservative

Manufacturer,
Blinatumomab
42 42 42 42
38.5 mcg 3 mL SWI 12.5 mcg/mL 24 h F, 4 h RT 250 mL NS complete - use non-DEHP bag
(Amgen) administration within and IV administration
42 42
(F)(PFL) do NOT use add supplied IV 10 d F, 96 h RT set
do not shake supplied IV solution solution stabilizer to - use 0.2 or 0.22
42 42
no preservative stabilizer to NS bag and gently micron in-line filter
42
reconstitute vials mix to avoid - prime lines with
42
foaming blinatumomab
direct diluent against solution; do NOT use
side of vial during add reconstituted NS
42
reconstitution drug to bag following
addition of IV solution
42
gently swirl to avoid stabilizer
42
excess foaming
Bortezomib
43 43 44,45 43 44,45
SC injection 1.4 mL NS 2.5 mg/mL 2 d F, RT SC syringe 14 d F, 48 h RT - auxiliary info:
3.5 mg WARNING:
(Actavis) SUBCUTANEOUS
(RT)(PFL) use only. Fatal if
43
no preservative given by other
routes.
Bortezomib
43 43 44,45 43 44,45
3.5 mg 3.5 mL NS 1 mg/mL 2 d F, RT IV syringe 14 d F, 48 h RT - auxiliary info:
(Actavis) WARNING:
(RT)(PFL) INTRAVENOUS use
43
no preservative only. Fatal if given by
other routes.

Manufacturer,
Bortezomib
46 46 30,47 46 30,47
SC injection 1.4 mL NS 2.5 mg/mL 2d F, RT SC syringe 14 d F, 48 h RT - auxiliary info:
3.5 mg WARNING:
(Apotex) SUBCUTANEOUS
46
routes.
Bortezomib
46 46 30,47 46 30,47
3.5 mg 3.5 mL NS 1 mg/mL 2d F, RT IV syringe 14 d F, 48 h RT - auxiliary info:
(Apotex) WARNING:
46
other routes.
Bortezomib
48 48 44,45 48 44,45
3.5 mg WARNING:
(Janssen) SUBCUTANEOUS
48
routes.
Bortezomib
48 48 44,45 48 44,45
(Janssen) WARNING:
48
other routes.

Manufacturer,
Bortezomib
49 49 44,45 49 44,45
3.5 mg WARNING:
(Teva) SUBCUTANEOUS
49
routes.
Bortezomib
49 49 44,45 49 44,45
(Teva) WARNING:
49
other routes.
Brentuximab vedotin
50 50 50 50
50 mg 10.5 mL SWI 5 mg/mL 24 h F 0.4-1.8 mg/mL in NS, 24 h F - solution should be
(GMD/Seattle Genetics) D5W, Lactated clear to slightly
(F)(PFL) direct diluent against Ringer’s opalescent,
50
no preservative side of vial during colorless, and free of
50 50 50
reconstitution 100-250 mL visible particulates
50
do NOT shake

Manufacturer,
Busulfan
51
60 mg/10 mL N/A 6 mg/mL discard unused NS, D5W complete - contains DMA***
30,51
(PMS) portion (dilute to volume 10 administration within - always add
51
(F) times drug volume to 12 h F, 8 h RT busulfan to diluent to
51
no preservative achieve final mix; do not add
51
concentration of ~0.5 diluent to busulfan
51
mg/mL)
Busulfan
52
60 mg/10 mL N/A 6 mg/mL discard unused NS, D5W in NS: complete - contains DMA***
18,52
(SteriMax) portion (dilute to volume 10 administration within - always add
52
(F) times drug volume to 12 h F, 8 h RT busulfan to diluent to
52
no preservative achieve final mix; do not add
52
concentration of ~0.5 in D5W: complete diluent to busulfan
52
mg/mL) administration within
52
8 h RT

Manufacturer,
Cabazitaxel
53 53
60 mg/1.5 mL supplied diluent: 10 mg/mL 1 h RT 0.10 – 0.26 mg/mL complete - concentrate and
53
(sanofi-aventis) withdraw entire NS, D5W administration within diluent vials contain
53 53
(RT) contents of diluent 48 h F, 8 h RT overfill
53
no preservative vial and inject into (e.g., 250 mL*) - use non-DEHP bag
53
the concentrate and tubing
53
vial - use 0.22 micron in-
53
line filter
slowly direct diluent - diluent contains
against inside of vial 13% (w/w) ethanol in
53 53
to limit foaming water
- discard if
mix by repeated crystallization
53
inversions for 45 occurs
53
sec
53
do NOT shake
53
let sit for 5 min
CARBOplatin
54 54 54
50 mg/5 mL N/A 10 mg/mL discard unused 0.5-10 mg/mL 24 h F, 8 h RT - do NOT use
54
150 mg/15 mL portion aluminum-containing
54
450 mg/45 mL NS, D5W needle, syringe, or
54
600 mg/60 mL tubing
(Accord)
(RT)(PFL)
54
no preservative

Manufacturer,
CARBOplatin
55 55 55 56
50 mg/5 mL N/A 10 mg/mL discard unused 0.3-10 mg/mL 48 h F , 24 h RT - do NOT use
55
55
450 mg/45 mL NS, D5W needle, syringe or
55
600 mg/60 mL tubing
(Omega)
(RT)(PFL)
55
no preservative
CARBOplatin
57 57 57
50 mg/5 mL N/A 10 mg/mL discard unused 0.3-10 mg/mL 48 h F - do NOT use
57
57
57
600 mg/60 mL tubing
(Pfizer/Hospira)
(RT)(PFL)
57
no preservative
CARBOplatin
58 59 58
50 mg/5 mL N/A 10 mg/mL discard unused 0.5-10 mg/mL 8 h RT - do NOT use
58
150 mg/15 mL portion RT aluminum-containing
58,60,61
58
(Teva/Novopharm) tubing
(RT)(PFL)
58
no preservative

Manufacturer,
Carfilzomib
62 62
10 mg 10 mg: 2 mg/mL 24 h F, 4 h RT 50-100 mL D5W complete - if a closed system
62 62
30 mg 5 mL SWI only administration within transfer device is not
60 mg 24 h F, 4 h RT after used for
62 62
(Amgen) 30 mg: do NOT dilute in NS reconstitution compounding, a 21
62
(F)(PFL) 15 mL SWI gauge (or larger
62
no preservative gauge) needle is
60 mg: recommended to
62
29 mL SWI prevent coring of the
62-64
vial stopper
direct diluent against
side of vial during
62
reconstitution
swirl gently; do NOT

62
shake
if foaming occurs,
allow to settle until
clear (about 5
62
minutes)
record time of
reconstitution

Manufacturer,
Carmustine
65 65 65
100 mg 3 mL diluent 3.3 mg/mL in 10% 24 h F, 8 h RT glass or polyolefin 24 h F: in glass or - do not use if
65 65 60 60
(Bristol Labs) (supplied) ethanol container polyolefin container product has oily
65
(F) droplets
65 65
no preservative diluent to reach RT, 500 mL NS or D5W use within 4 h of
65
then dissolve drug reconstitution RT
with 3 mL diluent;
65
add 27 mL SWI
record time of
reconstitution
Cemiplimab
66
250 mg/5 mL N/A 50 mg/mL discard unused 50 or 100 mL NS, complete
66 66
(Regeneron) portion D5W administration within
66
(F)(PFL) 24 h F, 6 h RT
do not shake dilute to final volume
66
no preservative by withdrawing
volume from bag
equal to volume of
66
drug to be added
mix by gentle
inversion

Manufacturer,
Cetuximab
67 67 67 67
100 mg/50 mL N/A 2 mg/mL 12 h F, 8 h RT syringe 12 h F, 8 h RT - administer using
67
200 mg/100 mL 0.22 micron filter
(Imclone/Lilly)
(F) evacuated container
67
do not shake or bag
67
no preservative
CISplatin
68 68
10 mg/10 mL N/A 1 mg/mL discard unused Less than or equal to 24 h RT - do NOT use
30
50 mg/50 mL portion 60 mg: 100 mL* NS aluminum-containing
100 mg/100mL needle, syringe or
68
(Accord) Greater than 60 mg: tubing
(RT)(PFL) 250 mL* NS
68
no preservative
2 L of D5 in one-half
or one-third NS
containing 37.5 g of
68
mannitol
CISplatin
69 69
30
100 mg/100mL portion 60 mg: 100 mL* NS aluminum-containing
(Pfizer/Hospira) needle, syringe or
69
(RT)(PFL) Greater than 60 mg: tubing
69
no preservative 250 mL* NS
or one-third NS
69
mannitol

Manufacturer,
CISplatin
70 70,71 70
10 mg/10 mL N/A 1 mg/mL 48 h RT Less than or equal to 24 h RT - do NOT use
50 mg/50 mL 60 mg: 100 mL NS* aluminum-containing
70
(Sandoz) Greater than 60 mg: tubing
(RT)(PFL) 250 mL NS*
70
no preservative
NS, 0.45% sodium
chloride with or
72
without mannitol
or one-third NS
70
mannitol
CISplatin
73 73
18
50 mg/50 mL portion 60 mg: 100 mL* NS aluminum-containing
73
(Teva) Greater than 60 mg: tubing
(RT)(PFL) 250 mL* NS
73
no preservative
or one-third NS
73
mannitol

Manufacturer,
Cladribine
74 75
10 mg/10 mL N/A 1 mg/mL discard unused SC syringe discard end of
74 13,74,76
(Fresenius Kabi) potion day
(F)(PFL)
74
no preservative
500 mL NS only 24 h RT
do NOT use D5W
74
Cassette: at least 7 days
qs to 100 mL with
bacteriostatic NS
only via SIMS
DELTEC INC.
MEDICATION
74
CASSETTES® filter
drug and diluent
through 0.22 micron
filter as each solution
is being introduced
into the cassette

Manufacturer,
Cyclophosphamide
77 71,77,79 77,79
200 mg 200 mg: 20 mg/mL 48 h F, Less than or equal to 72 h F,
77 77
500 mg 10 mL NS 24 h RT 1 g: 100 mL NS* 24 h RT
1000 mg
2000 mg 500 mg: Greater than 1 g:
(Baxter) 25 mL NS 250 mL NS*
(RT)(PFL)
77
no preservative 1000 mg: high dose in BMT:
50 mL NS may need 500 NS*
77
2000 mg: NS, D5W, D5NS
77,78
100 mL NS
Cytarabine
80 80
1000 mg/10mL N/A 100 mg/mL discard unused 0.1-37.5 mg/mL NS, 10 d F, 48 h RT
30,80 80
2000 mg/20mL portion D5W, SWI
(Pfizer/Hospira) **(PFL)
(RT)(PFL) 100 mL* NS, D5W,
80
no preservative SWI
Cytarabine
80
IT injection N/A 100 mg/mL use within 4 h of diluents containing use within 4 h of - auxiliary info: IT
30 30
1000 mg/10mL initial vial preservatives should initial vial puncture injection
30
2000 mg/20mL record time of puncture NOT be used for - label to include
(Pfizer/Hospira) puncture intrathecal **(PFL) route in full (i.e.,
80
(RT)(PFL) administration INTRATHECAL
80
no preservative injection) attached to
qs to 6 mL with both syringe and
41
preservative free outer ziplock bag
81,82
NS

Manufacturer,
Cytarabine
80 80
SC injection N/A 100 mg/mL discard unused syringe 10 d F, 48 h RT
30,80
1000 mg/10mL portion
2000 mg/20mL **(PFL)
(Pfizer/Hospira)
(RT)(PFL)
83
no preservative
Cytarabine
84 84
1000 mg/10mL N/A 100 mg/mL discard unused 0.1-37.5 mg/mL NS, 10 d F, 48 h RT
30,84 84
2000 mg/20mL portion D5W, SWI
(PMS) **(PFL)
(RT)(PFL) 100 mL* NS, D5W,
84
no preservative SWI
Cytarabine
84
IT injection N/A 100 mg/mL use within 4 h of diluents containing use within 4 h of - auxiliary info: IT
30 30
1000 mg/10mL initial vial preservatives should initial vial puncture injection
30
2000 mg/20mL record time of puncture NOT be used for - label to include
(PMS) puncture intrathecal **(PFL) route in full (i.e.,
84
(RT)(PFL) administration INTRATHECAL
84
no preservative injection) attached to
qs to 6 mL with both syringe and
41
preservative free outer ziplock bag
81,82
NS

Manufacturer,
Cytarabine
84 84
SC injection N/A 100 mg/mL discard unused syringe 10 d F, 48 h RT
30,84
1000 mg/10mL portion
2000 mg/20mL **(PFL)
(PMS)
(RT)(PFL)
84
no preservative
Dacarbazine
85 85 85
100 mg 100 mg: 10 mg/mL 72 h F, 8 h RT 250-1000 mL* NS, 24 h F, 8 h RT - protect container
85
200 mg 9.9 mL SWI D5W from light during
60,85
(Abraxis) **(PFL) storage and
86
(F)(PFL) 200 mg: administration
85 85
no preservative 19.7 mL SWI - overfill unknown
Dacarbazine
87 87 13,87 87
200 mg 200 mg: 10 mg/mL 8 h RT, 48 h F 0.19–3.0 mg/mL 24 h F - protect container
87
600 mg 19.7 mL SWI from light during
88 86
(Hospira) (PFL) 250-1000 mL* NS, **(PFL) storage and
86
(F)(PFL) 600 mg: D5W administration
87 87 88,89
no preservative 59.1 mL SWI - no overfill
Dacarbazine
90 90 90 90
600 mg 59.1 mL SWI 10 mg/mL 24 h F, 8 h RT 0.19-3.0 mg/mL in 24 h F - protect container
90
(Pfizer) D5W or NS from light during
86
(F)(PFL) **(PFL) storage and
90 86
no preservative administration

Manufacturer,
DACTINomycin
91
0.5 mg 1.1 mL SWI 0.5 mg/mL discard unused syringe use within 4 h of - drug loss reported
91 91 71 71
(GMD Pharma for (preservative-free) (500 mcg/mL) portion initial vial puncture with some cellulose
Recordati) ester membrane in-
91
(RT)(PFL) do NOT use SWI 10 mcg/mL or line filters
91 91
no preservative with preservative greater
(may form
91 91,92
precipitate) NS, D5W
Daratumumab
93
100 mg/5mL N/A 20 mg/mL discard unused 500-1000 mL NS 24 h F, followed by - administer with a
93
400 mg/20mL portion 15 h infusion (total 39 0.22 or 0.2 micron in-
93 93
(Janssen) dilute to final volume h) line filter
(F)(PFL) by withdrawing - discard if visible
do not shake volume from bag allow bag to come to particles are
93 93
no preservative equal to volume of room temperature, observed
93
drug to be added then use - complete infusion
93 93
immediately within 15 hours
mix by gentle
93
inversion **(PFL)
DAUNOrubicin
94 94,97 96 94
20 mg 4 mL SWI 5 mg/mL 48 h F, 24 h RT 100-250 mL in 48 h F, 24 h RT
94
(Erfa Canada Inc.) isotonic solution e.g.,
95 94
(RT)(PFL) NS
96
no preservative
96
no data for D5W

Manufacturer,
DAUNOrubicin
98 98 98 98
20 mg 4 mL SWI 5 mg/mL 48 h F, 24 h RT 100-250 mL 48 h F, 24 h RT
60
(Teva/Novopharm) NS or D5W
98 98
(RT)(PFL) **(PFL) **(PFL)
98
no preservative
Degarelix
99 99 99 99
80 mg 80 mg: 20 mg/mL 2 h RT SC syringe 2 h RT
120 mg 4.2 mL SWI
99
(Ferring) (supplied diluent)
(RT)
99
do not shake
100 99
no preservative 120 mg: 40 mg/mL
3 mL SWI (supplied
99
diluent)
swirl gently; avoid

shaking to prevent
99
foam formation
reconstitution may
99
take up to 15 min

Manufacturer,
Denosumab
101 101
(XGEVA) N/A 71 mg/mL discard unused SC syringe use within 4 h of - not interchangeable
71,101 71 101
120 mg/1.7 mL portion initial puncture with PROLIA
(Amgen) - do not use if
(F)(PFL) solution is cloudy;
do not shake trace amounts of
101
no preservative translucent to white
proteinaceous
particles are
101
acceptable
- avoid vigorous
101
shaking
- bring to room
temperature 15-30
minutes prior to
101
administration
Dexrazoxane
102 102
250 mg 250 mg: 10 mg/mL 3 h F, 30 min MUST BE FURTHER 4 h F, 1 h RT
102 103
500 mg 25 mL SWI RT DILUTED With
(Pfizer) Lactated Ringers
(RT) 500 mg: Injection to 1.3 – 3.0
102 102 102
no preservative 50 mL SWI mg/mL

Manufacturer,
DOCEtaxel
104 104
20 mg/2 mL N/A 10 mg/mL 20mg/2 mL vial: 0.3-0.74 mg/mL complete - use non-DEHP bag
80 mg/8 mL discard unused administration within and IV administration
18,104 104 104
160 mg/16 mL portion 250 mL* NS, D5W 14 d F, 48 h set
18,105,106
(Pfizer/Hospira) RT
(F, RT)(PFL)
104
preservative 80 mg/8 mL or
160 mg/16 mL
104
vial (maximum
number of
punctures: up to 3
doses can be
removed when a
venting needle is
also inserted, i.e.,
6 punctures
106
total)
18,104
14 d F
104
**(PFL)
DOCEtaxel
107 18,108 107
20 mg/2 mL N/A 10 mg/mL 14 d F, RT 0.3-0.74 mg/mL complete - use non-DEHP bag
80 mg/8 mL administration within and IV administration
107 107,109 107
160 mg/16 mL 250 mL* NS, D5W 24 h F, 4 h RT set
(Sandoz)
(F,RT)(PFL)
107
preservative

Manufacturer,
DOCEtaxel
110 18,110,111 110
20 mg/0.5 mL supplied diluent : 10 mg/mL 14 d F, RT 0.3-0.74 mg/mL complete - use non-DEHP
80 mg/2 mL - if vials were administration within bag and IV
110 110 110
(sanofi-aventis) refrigerated, allow to 250 mL NS, D5W 4 h F, administration set
18,111
(F, RT)(PFL) warm for 5 min at 48 h RT
110
no preservative RT. Withdraw entire
contents of the
diluent and inject the
entire contents of
the syringe into the
corresponding
concentrate vial. Mix
by repeated
inversions for 45
110
sec
110
do NOT shake
Let sit for 5

110
minutes
DOXOrubicin
112 112 112
10 mg/5 mL N/A 2 mg/mL 8h syringe 24 h F, RT from initial - for ULYEPOCHR
112
20 mg/10 mL vial puncture protocol, see entry
50 mg/25 mL for EPOCHR
200 mg/100 mL (3-in-1solution
(Accord) containing
(F)(PFL) etoposide,
112
no preservative DOXOrubicin,
vinCRIStine)

Manufacturer,
DOXOrubicin
113 113 13,114
10 mg 10 mg: 2 mg/mL 48 h F, 24 h syringe 48 h F, 24 h RT - for ULYEPOCHR
13,113
50 mg 5 mL NS, SWI, RT protocol, see entry
113
150 mg D5W for EPOCHR
(Hospira) (3-in-1solution
(RT)(PFL) 50 mg: containing
113
no preservative 25 mL NS, SWI, etoposide,
113
D5W DOXOrubicin,
vinCRIStine)
150 mg:
75 mL NS, SWI,
113
D5W
(NS reconstitution
113
takes longer)
DOXOrubicin
115 115 115 115
10 mg/5 mL N/A 2 mg/mL 8h syringe 48 h F, 24 h RT - for ULYEPOCHR
20 mg/10 mL from initial vial protocol, see entry
50 mg/25 mL record time of puncture for EPOCHR
200 mg/100 mL puncture (3-in-1solution
(Teva/Novopharm) containing
(F)(PFL) etoposide,
115
no preservative DOXOrubicin,
vinCRIStine)

Manufacturer,
DOXOrubicin
116 116 116
10 mg/5 mL N/A 2 mg/mL discard unused syringe 48 h F, 24 h RT - for ULYEPOCHR
71,116
50 mg/25 mL portion protocol, see entry
200 mg/100 mL for EPOCHR
(Pfizer) (3-in-1solution
(F) containing
116
no preservative etoposide,
DOXOrubicin,
vinCRIStine)
DOXOrubicin
117 117 117
Pegylated Liposomal N/A 2 mg/mL discard unused Less than 90 mg: 250 24 h F - do not filter
117 117
20 mg/10 mL portion mL D5W only
(Janssen)
(F) Greater than or equal
117
no preservative to 90 mg: 500mL
117
D5W only
Durvalumab
118 118 118
120 mg/2.4 mL N/A 50 mg/mL discard unused 1-15 mg/mL NS, 24 h F, 4 h RT - do NOT shake
118 118
500 mg/10 mL portion D5W - use 0.2-0.22 micron
(AstraZeneca) in-line filter to
118
(F)(PFL) (e.g., 100 mL* NS, administer
do not shake D5W)
118
no preservative
mix by gentle
118
inversion

Manufacturer,
Epirubicin
119 119 119
10 mg/5 mL N/A 2 mg/mL 8 h F, RT syringe 48 h F, 24 h RT
20 mg/10 mL from initial vial
119
50 mg/25 mL puncture
150 mg/75 mL
200 mg/100 mL
(Teva/Novopharm)
(F)(PFL)
119
no preservative
Epirubicin
120 120 120
10 mg/5 mL N/A 2 mg/mL 8h syringe 48 h F, 24 h RT
50 mg/25 mL from initial vial
120
200 mg/100 mL record time of puncture
(Fresenius Kabi) puncture
(F)(PFL)
120 18,120
no preservative 100 mL* NS, D5W 2 d F, RT
Epirubicin
121 121 121
10 mg/5 mL N/A 2 mg/mL 8h syringe 48 h F, 24 h RT from
121
50 mg/25 mL initial vial puncture
200 mg/100 mL record time of
(Pfizer) puncture
60 122
(F)(PFL) 100 mL* NS, D5W 2 d F, RT
121
no preservative

Manufacturer,
EPOCHR
(ULYEPOCHR protocol) see brand specific see brand specific see brand etoposide dose etoposide - final product is a
(RT) entries for: entries for: specific entries ≤125 mg/24 h: concentration 3-in-1 solution
18,123-126
no preservative DOXOrubicin as DOXOrubicin, for: DOXOrubicin, in 500 mL NS ≤0.25 mg/mL: containing
applicable etoposide, etoposide, complete etoposide,
vinCRIStine vinCRIStine etoposide dose administration within DOXOrubicin,
>125 mg/24 h: 72 h RT vinCRIStine (refer to
in 1000 mL NS ULYEPOCHR
precipitation occurs protocol)
at etoposide - use non-DEHP bag
concentrations and tubing only
>0.25 mg/mL - use 0.22 micron
inline filter
eriBULin
127 127 127
1 mg/2 mL N/A 0.5 mg/mL discard unused IV syringe 24 h F, 6 h RT - do not administer
18,127
(Eisai Limited) portion through dextrose
127 127
(RT)(PFL) containing lines
18
no preservative - vials contain
dehydrated alcohol
127
USP (5% v/v)

Manufacturer,
Etoposide
128 128
100 mg/5 mL N/A 20 mg/mL 14 d RT 0.2-0.4 mg/mL NS, 0.2 mg/mL: - use non-DEHP bag
128 128
200 mg/10 mL D5W 7 d F, RT and tubing only
500 mg/25 mL - use 0.22 micron in-
129
1000 mg/50 mL 500 mL* NS, D5W 0.4 mg/mL: line filter
128
(Sandoz) 12 h F, RT - for ULYEPOCHR
(RT)(PFL) protocol, see entry
128
preservative for EPOCHR
(3-in-1solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)

Manufacturer,
Etoposide
130
100 mg/5 mL N/A 20 mg/mL discard unused NS 0.2-0.3 mg/mL: - use non-DEHP bag
130 131 131,132
200 mg/10 mL portion 7 d F, 2 d RT and tubing only
500 mg/25 mL Stability is - use 0.22 micron in-
129
1000 mg/50 mL concentration 0.4-0.5 mg/mL: line filter
131 131
(Teva/Novopharm) dependent 1 d F, 1d RT - for ULYEPOCHR
(RT)(PFL) protocol, see entry
130
no preservative 0.6-9.0mg/mL: for EPOCHR
generally unstable (3-in-1solution
containing
9.5 mg/mL: etoposide,
131 131
2 d F, 1d RT DOXOrubicin,
vinCRIStine)
10-12 mg/mL:
131 131,132
7 d F, 2 d RT
130 130,133
D5W 4 h RT
Etoposide phosphate
134,135 18,134,135 134,135
(ETOPOPHOS®) 5 mL NS, D5W, 20 mg/mL 48 h F , 24 500 mL* NS, 24 h F, RT
134,135 134,135 134,135
100 mg SWI, BWI h RT , D5W
(BMS)
(F)(PFL) (do not dilute to less
134 134,135 134,135
no preservative 10 mL NS, D5W, 10 mg/mL than 0.1 mg/mL)
134,135
SWI, BWI

Manufacturer,
Filgrastim
136 136 18,137
(NEUPOGEN®) N/A 300 mcg/mL discard unused SC syringe 14 d F - albumin is added to
18
300 mcg/1 mL portion D5W to prevent
480 mcg/1.6 mL filgrastim adsorption
18,137 136
(Amgen) 50-100 mL D5W 7 d F, 48 h RT to plastic
138
(F)(PFL) only - incompatible with
136,138
do not shake saline
136
no preservative in PVC, polyolefin, or - do NOT dilute to
136
glass less than 5
136
mcg/mL
(for filgrastim
concentrations of 5-
15 mcg/mL in D5W,
add albumin 2
136
mg/mL)
Fludarabine
139 139 13,122 13,122
50 mg 2 mL SWI 25 mg/mL 48 h F, RT dilute to maximum of 48 h F, RT
139,140
(Berlex) 1 mg/mL
(F)
139
no preservative 50-100 mL NS,
139
D5W
Fludarabine
141 141
50 mg N/A 25 mg/mL discard unused dilute to maximum of 48 h F, 24 h RT
141 141
(Teva/Novopharm) portion 1 mg/mL
(F)
141
no preservative (e.g., 50-100 mL* NS,
D5W)

Manufacturer,
Fluorouracil
142 18,143 142 18,143
5000 mg/100 mL N/A 50 mg/mL 48 h RT syringe 48 h RT
(Accord)
(RT)(PFL)
142 143 18,143
no preservative 0.5-10 mg/mL 48 h RT
(e.g., 50-1000 mL*

D5W)
CIVI: ambulatory complete within 8

144 143
pump d
Fluorouracil
145 145 145 30,145
(Pfizer/Hospira)
(RT)(PFL)
145 146 145
no preservative 0.5-10 mg/mL 24 h RT
(e.g., 50-1000 mL*

D5W)
CIVI: ambulatory complete within

144 13,60,147,148
pump 8d

Manufacturer,
Fluorouracil
149 30,150 30,149
5000 mg/100 mL
(Sandoz)
150 30,150
(RT)(PFL) 0.35 – 15 mg/mL 48 h RT
149
no preservative
149
(300-500 mL D5W)
CIVI: ambulatory complete within

144 13,60,147,148
pump 8d
Gemcitabine
151 151 151 151
200 mg 200 mg: 38 mg/mL 24 h RT syringe 24 h RT
151
1000 mg 5 mL NS
2000 mg
151 18,152,153
(Accord) 1000 mg: 0.1-38 mg/mL NS 48 h RT
151
(RT) 25 mL NS
151
no preservative
2000 mg:
151
50 mL NS
Gemcitabine
155 155 154
200 mg/5.3 mL N/A 38 mg/mL discard unused syringe 24 h RT
154
1000 mg/26.3 mL portion
2000 mg/52.6 mL
(Pfizer/Hospira) 0.1–38 mg/mL NS,
154
(F) D5W
154
no preservative

Manufacturer,
Gemcitabine
156 156 156
(NOTE: concentration) N/A 40 mg/mL discard unused syringe 24 h RT - CAUTION:
156
200 mg/5 mL portion alternative
1000 mg/25 mL concentration
2000 mg/50 mL 0.1–38 mg/mL NS,
(Sandoz) D5W
156
(F)
156
no preservative
IDArubicin
157 157 157
5 mg 5 mg: 1 mg/mL 48 h F, syringe 48 h F, 24 h RT - avoid alkaline
157 157 157
10mg 5 mL SWI 24 h RT solutions
(Pfizer)
157
(RT)(PFL) 10 mg: **(PFL)
157 157
no preservative 10 mL SWI
vial contents under

157
negative pressure
do NOT use BWI to

157
reconstitute
IDArubicin PFS
157 157
5 mg/5 mL N/A 1 mg/mL 48 h F, 24 h RT, syringe 4 h from initial - avoid alkaline
18 157
10 mg/10 mL puncture solutions
157
20 mg/20 mL **(PFL)
(Pfizer)
(F)(PFL)
157
no preservative

Manufacturer,
IDArubicin
158 158
5 mg/5 mL N/A 1 mg/mL discard unused syringe 4 h from initial - avoid alkaline
158 18 158
10 mg/10 mL solution puncture solutions
20 mg/20 mL
(Fresenius Kabi)
(F)(PFL)
158
no preservative
Ifosfamide
159 159 159
1000 mg 1000 mg: 50 mg/mL 48 h F, 24 h 0.6–20 mg/mL 72 h F, 24 h RT
159 18,159
3000 mg 20 mL SWI RT
(Baxter) 500–1000 mL* NS, 24 h F, RT when
60
(RT) 3000 mg: D5W, Lactated mixed with mesna
159 159 159
no preservative 60 mL SWI Ringer’s
shake well
Ifosfamide
160 160 160
1000 mg 1000 mg: 50 mg/mL 48 h F, 24 h 0.6-20 mg/mL 72 h F, 24 h RT
160 18,160
3000 mg 20 mL SWI RT
(Fresenius Kabi) 24 h F, RT when
60
(RT) 3000 mg: 500-1000 mL* NS mixed with mesna
160 160
no preservative 60 mL SWI D5W, Lactated
160
Ringer’s
shake well

Manufacturer,
Iniparib
161 161
100 mg/10 mL N/A 10 mg/mL discard unused 250 mL NS, D5W 24 h RT - *may also use
161
(sanofi-aventis) portion empty IV bag and qs
(F) dilute to 250 mL final to final volume of
161
no preservative volume by 250 mL with NS,
161
withdrawing volume D5W
from bag equal to
volume of drug to be
161
added*
Inotuzumab
162 162 162 162
ozogamicin 4 mL SWI 0.25 mg/mL 4hF 0.01 – 0.1 mg/mL complete - do NOT shake
162
0.9 mg NS administration within - protect container
(Pfizer) gently swirl vial to record time of dilute dose within 8 h of reconstitution from UV and
162 162 162
(F)(PFL) mix reconstitution 4 hours of (50 mL NS) RT,F fluorescent light
162 162
no preservative reconstitution during storage and
162 162,163
(PFL) administration
protect from light mix by gentle - protect
162
if not used inversion if refrigerated, bring administration line
163
immediately bag to RT over 1 h from light ONLY if
prior to hang time will be
162 162,163
administration longer than 1 h
Interferon Alfa -2b

164 164 18
10 million units/1 mL N/A 10 million 7dF syringe 7dF - vials can be kept at
164
(Merck) units/mL RT for up to 7 days
(F) before use; discard if
164,165 164
preservative final concentration 24 h F, RT not used within this
164 164
≥ 0.3 million IU/mL time
164
50 mL NS

Manufacturer,
Interferon Alfa -2b
18,164 164 18,165
18 million units/3 mL N/A 6 million 14 d F syringe 14 d F - vials can be kept at
164
164,165 164
164 164
164
50 mL NS
Interferon Alfa -2b

18,164 164 18,165
25 million units/2.5 mL N/A 10 million 14 d F syringe 14 d F - vials can be kept at
164
164,165 164
164 164
164
50 mL NS

Manufacturer,
Interferon Alfa -2b
164 164 18,165
10 million units 1 mL supplied 10 million 24 h F syringe 24 h F - after reconstitution,
164 164
(Merck) diluent (SWI) units/mL provides an isotonic
(F) solution which may
no preservative (unless do NOT shake; roll be used for
164 165
reconstituted with to reconstitute final concentration 24 h F, RT intralesional
164 164 164
BWI) ≥ 0.1 million IU/mL injection
- non-reconstituted
164
100 mL NS vials can be kept at
RT for up to 4 weeks
before use; discard if
164 18,164 164 18,164
1 mL BWI 14 d F syringe 14 d F not reconstituted for
use within this
164
do NOT shake; roll time
164 165
to reconstitute final concentration 24 h F, RT
164
≥ 0.1 million IU/mL
164
100 mL NS

Manufacturer,
Ipilimumab
166 166 166 166
50 mg/10 mL N/A 5 mg/mL 24 h F,RT 1 – 4 mg/mL NS, 24 h F,RT - do NOT shake
166
200 mg/40 mL D5W - administer with 0.2
166
(BMS Canada) or 0.22 in-line filter
(F)(PFL) OR - vials may contain
166
no preservative undiluted in empty translucent-to-white
viaflex bag or glass amorphous
166
bottle particles
- discard if cloudy or
(allow vials to stand at has pronounced
RT for ~5 min prior to colour change
withdrawal of (should be clear to
166 166
contents) pale yellow)
Irinotecan
167
40 mg/2 mL N/A 20 mg/mL discard unused 0.12–3 mg/mL D5W 48 h F, 24 h RT
167 167
100 mg/5 mL portion (preferred), NS
167
500 mg/25 mL **(PFL)
60
(Accord) 500* mL
(RT)(PFL)
167
no preservative
Irinotecan
168,169
40 mg/2 mL N/A 20 mg/mL discard unused 0.12-3 mg/mL 14 d F, 48 h
168,169 30,168,169
100 mg/5 mL portion D5W (preferred), RT
168,169
300 mg/15 mL NS
500 mg/25 mL
60 168,169
(Pfizer/Hospira) 500* mL **(PFL)
(RT)(PFL)
168,169
no preservative

Manufacturer,
Irinotecan Liposome
170 170
43 mg/10 mL N/A 4.3 mg/mL discard unused to a final volume of 24 h F, 4 h RT - do not use in-line
170 170
(Servier) portion 500 mL with NS, filter
170
(F)(PFL) D5W **(PFL) - expressed as
170
no preservative irinotecan free base
mix by gentle (allow product to
170
inversion come to RT prior to
administration if
170
stored in F)
Ixabepilone
171 171 171
15 mg 15 mg: 2 mg/mL 1 h RT 0.2 – 0.6 mg/mL in 6 h RT - use 0.2-1.2 micron
171
(contains 16 mg) 8 mL supplied Lactated Ringer’s in-line filter
171
45 mg diluent Injection USP (use - use non-DEHP bag
(contains 47 mg) non-DEHP infusion and administration
171 171
(BMS) 45 mg: container) set
(F)(PFL) 23.5 mL supplied
171 171
no preservative diluent
* Suggested volume based on usual dose range and any concentration range of stability data
** Protect from light means minimizing exposure to direct sunlight over a storage period. More specific information on protection from light (eg, protecting container and tubing during
administration) will be indicated in the Special Precautions/Notes column.
*** Contains DMA (N,N dimethylacetamide). Product may be incompatible with closed system transfer devices such as ChemoLock.
Centres are not to change the content locally but should forward suggestions to the Cancer Drug Manual staff.

Explanatory Notes
Stability data assumes products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to
38,172
the classification outlined in USP 797.
Vial stability: Stability of solution after first puncture or reconstituted solution.
Storage temperature: If information states same stability with refrigerator and room temperature storage, then fridge stability is bolded as preferred
(ie, to minimize growth of micro-organisms).
Discard unused portion: Unused portion from single use vials should be discarded at the end of the day.
“overfill known” is stated if the manufacturer states overfill that is present is within acceptable limits.
“Complete administration within __” is stated if the manufacturer specifies that the infusion must be completed in a specific time frame following
preparation, usually including entire time required for preparation (from first puncture), storage, and administration of infusion.
Abbreviations
BWI = bacteriostatic water for injection
CIVI: ambulatory pump = Continuous Intravenous Infusion (e.g., elastomeric infusor)
D5W = dextrose 5% in water
DMA = N,N dimethylacetamide
F = refrigerate
Non-DEHP = not containing Di(2-ethylhexyl) phthalate (DEHP)
NS = normal saline
PFL = protect from light
RT = room temperature
SWI = sterile water for injection
References
1. Agensys. Pharmacy Guide Protocol AGS-16C3F-15-3: A multi-center, open label, randomized phase 2 study of AGS-16C3F vs. axitinib in metastatic renal cell carcinoma. Santa
Monica, California; 8 June 2016 - version 2.0.
2. BC Cancer. (Study Code GUT16C3F) Clinical Trial Dispensing Instructions for: A multi-center, open label, randomized phase 2 study of AGS-16C3F vs. aXitinib in metastatic renal
cell carcinoma. Vancouver, British Columbia: BC Cancer; 18 April 2018.
3. Laura Standley. Personal communication. Lead Clinical Study Manager, Astellas Pharma Global Development Inc.; 23 January 2019.
4. Novartis Pharmaceuticals Canada Inc. PROLEUKIN® product monograph. Dorval, Quebec; 6 July 2006.
5. McEvoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. p. 917-925.
6. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365(22):2055-2066.
7. Koreth J, Alyea EP, Cutler C, Ho VT, et al. Clinical Study Protocol: A phase I study of ultra-low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus
host disease. Boston, MA, USA: Dana Farber Cancer Institute; Harvard Medical Centre; 14 Dec 2010.
8. Rui Paiva. Personal communication. Business Unit Director, Transplant and Oncology; 1 June 2009.
9. Bayer HealthCare Pharmaceuticals. MabCampath® Package Insert. Toronto, Ontario; 1 September 2007.
10. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment
as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004(18):484-490.

11. Berlex Canada Inc. Campath Drug Information. San Antonio, Texas; undated.
12. Erfa Canada Inc. AMSA PD® injection product monograph. Westmount, Quebec; 16 August 2005.
13. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6 January 2006.
14. Tanya Leduc. Personal communication. Acting editor, BC Cancer Agency Cancer Drug Manual; 2 June 2008.
15. Lundbeck Canada Inc. TRISENOX® product monograph. Montreal, Quebec; 6 June 2013.
16. CGF Pharmatec for EUSA Pharma. KIDROLASE® product monograph. Montreal, Quebec; 17 April 2008.
17. Lexi-Drugs® (database on the Internet). Asparaginase (E. coli). Lexi-Comp Inc., 1 July 2015. Available at: http://online.lexi.com. Accessed 25 August 2015.
18. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September
2007.
19. CGF Pharmatec for EUSA Pharma. ERWINASE® for Injection product monograph. Montreal, Quebec; 19 February 2015.
20. Health Canada. MedEffect® e-Notice - Importnat Safety Information on Shortage of Erwinase for Injection. 12 July 2017. Available at: http://www.hc-sc.gc.ca/ahc-
asc/media/advisories-avis/. Accessed 12 July 2017.
21. Hoffman-La Roche Limited. TECENTRIQ® product monograph. 7070 Mississauga Road, Ontario; 12 April 2017.
22. Genentech Inc. TECENTRIQ® full prescribing information. South San Francisco, CA, USA; October 2016.
23. EMD Serono. BAVENCIO® product monograph. Mississauga, Ontario; 4 May 2018.
24. Celgene Inc. VIDAZA® product monograph. Mississauga, Ontario; 17 May 2012.
25. Kevin Mejo. Personal communication. Medical Information, Celgene Inc.; 21 June 2017.
26. Tutino A, Lai M. Cold water reconstitution of Vidaza with subsequent refrigerated storage prolongs drug stability. Eur J Oncol Pharm 2011;5(3-4):24-25, 34.
27. Celgene Corporation. VIDAZA® full prescribing information. Summit, NJ, USA; December 2012.
28. Dr. Reddy's Laboratories Limited. Azacitidine for injection product monograph. Mississauga, Ontario; 19 April 2017.
29. Merck Canada Inc. OncoTICE® product monograph. Kirkland, Quebec; 29 April 2019.
30. BC Cancer. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; 5 December 2018.
31. Merck & Co. Inc. TICE® BCG full prescribing information. Whitehouse Station, New Jersey, USA; March 2019.
32. Repchinsky C editor. ImmuCyst monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario; 2005.
33. Spectrum Pharmaceuticals Inc. BELEODAQ® full prescribing information. Irvine, CA, USA; April 2012.
34. Teva Canada Limited. TREANDA® product monograph. Toronto, Ontario; 10 January 2018.
35. Lundbeck Canada Inc. TREANDA® product monograph. Montreal, Quebec; 22 August 2012.
36. Roche. Bevacizumab for injection, Summary product information. Mississauga, Ontario; 2005.
37. Hoffmann-La Roche Limited. Ro 4876647 Avastin Investigator's Brochure. Mississauga, Ontario; 14th edition, November 2006.
38. The United States Pharmacopeia (USP). General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States
Pharmacopeial Convention, Inc.; 2004.
39. Fresenius Kabi Canada Ltd. Bleomycin for injection product monograph. Richmond Hill, Ontario; 1 June 2016.
40. Pfizer Canada Inc. Bleomycin for Injection product monograph. Kirkland, Quebec; 8 August 2017.
41. BC Cancer. Systemic Therapy Policy and Procedure III-50: Administration of High Alert Medications by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir.
Vancouver, British Columbia; 1 May 2019.
42. Amgen Canada Inc. BLINCYTO® product monograph. Mississauga, Ontario; 12 July 2016.
43. Actavis Pharma Company. ACT BORTEZOMIB® Bortezomib for injection product monograph. Mississauga, Ontario; 24 September 2015.
44. Law S, Charbonneau LF, Iazzeta J, et al. Stability of generic formulations of bortezomib 1.0 and 2.5 mg/mL in vials and syringes stored at 4°C and room temperature (23°C). CJHP
Canadian Society of Hospital Pharmacists Professional Practice Conference 2018 Poster Abstracts.Feb 4 - 6, 2018.
45. BC Cancer. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; 19 September 2007.
46. Apotex Inc. Bortezomib for injection product monograph. Toronto, Ontario; 15 February 2019.
47. SE Walker, S. Law and N. Ma. (Abstract) Stability of 1.0 and 2.5 mg/mL bortezomib solution in vials and syringes following reconstitution with 0.9% sodium chloride at 4ºC and
room temperature (25ºC). (Apotex brand). Department of Pharmacy, Sunnybrook Health Sciences Centre and Leslie Dan Faculty of Pharmacy, University of Toronto; 2019.
48. Janssen Inc. VELCADE® product monograph. Toronto, Ontario; 20 June 2013.
49. Teva Canada Limited. Bortezomib for injection® product monograph. Toronto, Ontario; 22 January 2015.
50. GMD Distribution Inc. for Seattle Genetics Inc. ADCETRIS® product monograph. Oakville, Ontario; 1 February 2013.

51. Pharmascience Inc. Busulfan for injection product monograph. Montreal, Quebec; 14 June 2018.
52. SteriMax Inc. Busulfan for injection product monograph. Oakville, Ontario; 4 May 2017.
53. sanofi-aventis Canada Inc. JEVTANA® product monograph. Laval, Quebec; 13 September 2013.
54. Accord Healthcare Inc. Carboplatin injection® product monograph. Kirkland, Quebec; 15 May 2019.
55. Omega Laboratories Ltd. Carboplatin injection product monograph. Montreal, Quebec; 24 March 2011.
56. Nayla El Zir. Personal communication. Associate, Regulatory Affairs, Omega Laboratories Limited; 12 April 2017.
57. Pfizer Canada ULC. Carboplatin injection product monograph. Kirkland, Quebec; 31 December 2018.
58. Novopharm Limited. Carboplatin Package Insert. Toronto, Canada; Undated.
59. Manjinder S Kang. Personal communication. Regulatory Affairs Drug Information Pharmacist, Novopharm Canada. 14 March 2005.
60. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005.
61. Repchinsky C editor. Paraplatin-AQ, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004.
62. Amgen Canada Inc. KYPROLIS® product monograph. Mississauga, Ontario; 6 July 2017.
63. Luis Simao. Personal communication. Area Manager, ICU Medical Canada; 11 May 2018.
64. Diane Lord. Personal communication. Medical Information, Amgen Canada Inc.; 8 May 2018.
65. Bristol Laboratories of Canada. BiCNU Package Insert. Montreal, Canada; 2002.
66. Regeneron Pharmaceuticals Inc. Pharmacy Manual Protocol R2810-ONC-1676: An open-label, randomized, phase 3 clinical trial of REGN2810 versus therapy of investigator's
choice chemotherapy in recuurent or metastatic platinum cervical cancer. Tarrytown, NY, USA; 26 July 2017 - version 1.0.
67. ImClone LLC (distributed by Eli Lilly Canada Inc). ERBITUX® product monograph. Toronto, Ontario; 10 January 2018.
68. Accord Healthcare Inc. Cisplatin injection product monograph. Kirkland, Quebec; 15 February 2019.
69. Pfizer Canada ULC. Cisplatin injection product monograph. Kirkland, Quebec; 7 December 2018.
70. Sandoz Canada Inc. Cisplatin Injection BP product monograph. Boucherville, Quebec; 13 April 2011.
71. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September
2007.
72. Trissel LA. Handbook on Injectable Drugs. 16th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2011. p. 378.
73. Teva Canada Limited. Cisplatin injection® product monograph. Toronto, Ontario; 6 March 2013.
74. Pharmaceutical Partners of Canada, Inc. Cladribine For Injection product monograph. Richmond Hill, Ontario; 27 November 2008.
75. BC Cancer Agency Lymphoma Tumour Group. (LYCDA) BCCA Protocol Summary for Treatment of Hairy Cell Leukemia with Cladribine. Vancouver, British Columbia: BC Cancer
Agency; 1 February 2007.
76. de Lemos ML, Hamata L. Stability issues of parenteral chemotherapy drugs. J Oncol Pharm Pract 2007;13(1):27-31.
77. Baxter Corporation. Procytox Package Insert. Toronto, Ontario; 2004.
78. Baxter Corporation. Procytox Package Insert. Missisauga, Ontario; 1 October 2003.
79. Paul Agro. Personal communication. Medical Information, cyclophosphamide, Baxter. 12 July, 2006.
80. Pfizer Canada Inc. Cytarabine Solution for Injection product monograph. Kirkland, Quebec; 3 November 2015.
81. BC Cancer Lymphoma Tumour Group. (LYIT) BC Cancer Protocol Summary for Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine. Vancouver, British
Columbia: BC Cancer; 1 June 2014.
82. BC Cancer Miscellaneous Origin Tumour Group. (MOIT) BC Cancer Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine.
Vancouver, British Columbia: BC Cancer; 1 October 2018.
83. Hospira Healthcare Corporation. Cytarabine Injection® product monograph. Saint-Laurent, Quebec; 25 November 2013.
84. Pharmascience Inc. Cytarabine Solution for Injection product monograph. Montreal, Quebec; 14 February 2017.
85. Abraxis Pharmaceutical Products. Dacarbazine product information package. Schaumburh, IL; December 2006.
86. Trissel L. Handbook on injectable drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists; 2005. p. 428-431.
87. Mayne Pharma (Canada) Inc. DACARBAZINE FOR INJECTION product monograph. Montreal, Quebec; 25 July 2003.
88. John Korontzis. Personal communication. Regulatory Affairs Associate, Dacarbazine, Mayne Pharma Canada; #FEB-14-2005 (february 8, 2005).
89. Robert Caunce. Personal communication. Quality System Manager, Hospira Australia; 12 March 2008.
90. Pfizer Canada Inc. Dacarbazine for Injection product monograph. Kirkland, Quebec; 31 May 2018.
91. Recordati Rare Diseases Inc. COSMEGEN® product monograph. Lebanon, New Jersey USA; 24 July 2014.

92. Andy Harbrow. Personal communication. Global Medical Services Manager, Primevigilance (for Recordati Rare Diseases Inc.); 15 July 2014.
93. Janssen Inc. DARZALEX® product monograph. Toronto, Ontario; 29 June 2016.
94. Erfa Canada Inc. Daunorubicin injection product monograph. Westmount, Quebec; 6 December 2002.
95. Erfa Canada Inc. Material Safety Data Sheet. Montreal, Quebec; 3 October 2007.
96. Henri Knafo MD. Personal communication. Medical Director, Erfa Canada Inc; 14 July 2008.
97. Henri Knafo MD. Personal communication. Medical director, Erfa Canada Inc; 09 July 2008.
98. Novopharm Limited. Daunorubicin Package Insert. Toronto, Canada; Undated.
99. Ferring Pharmaceuticals. FIRMAGON® product monograph. North York, Ontario; 20 March 2013.
100. Ferring Pharmaceuticals. FIRMAGON® product monograph. North York, Ontario; 06 November 2009.
101. Amgen Canada Inc. XGEVA® product monograph. Mississauga, Ontario; 14 October 2011.
102. Pfizer Canada Inc. ZINECARD® product monograph. Kirkland, Quebec; 12 August 2010.
103. Pfizer Canada Inc. ZINECARD® product monograph. Kirkland, Quebec; 30 March 2015.
104. Pfizer Canada Inc. Docetaxel injection product monograph. Kirkland, Quebec; 1 June 2018.
105. Hospira Canada Clinical Support Team. Personal communication. Hospira Canada Healthcare Corporation; 21 March 2011.
106. Josee Lloyd, Senior Clinical Specialist. Subject : Docetaxel Injection 160mg/16mL and 80 mg/8mL multidosing and venting needles. Hospira Clinical Support Team, Hospira
Healthcare Corporation; 13 July 2011.
107. Sandoz Canada Inc. Docetaxel injection product monograph. Boucherville, Quebec; 24 January 2018.
108. Bazundama Bazuta Feza Sandrine. Personal communication - regarding in-house vial stability for docetaxel injection. Medical Information Intern, Sandoz Canada Inc.; 14 August
2018.
109. Bazundama Bazuta Feza Sandrine. Personal communication - regarding in-house product stability of diluted docetaxel injection. Medical Information Intern, Sandoz Canada Inc.;
14 August 2018.
110. sanofi-aventis Canada Inc. TAXOTERE® product monograph. Laval, Quebec; 15 April 2011.
111. Walker SE, Charbonneau F, Law S. Stability of docetaxel solution after dilution in ethanol and storage in vials and after dilution in normal saline and storage in bags. Can J Hosp
Pharm 2007;60(4):231-237.
112. Accord Healthcare Inc. Doxorubicin injection® product monograph. Montreal, Quebec; 9 April 2014.
113. Mayne Pharma (Canada) Inc. Doxorubicin Package Insert. Montreal, QC; Undated.
114. Mayne Pharma (Canada) Inc. Doxorubicin Product Monograph. Montreal, Quebec; 2002.
115. Novopharm Limited. Doxorubicin Product Monograph. Scarborough, Ontario; 8 November 1996.
116. Pfizer Canada Inc. ADRIAMYCIN® injection product monograph. Kirkland, Quebec; 28 August 2007.
117. Janssen Inc. CAELYX® product monograph. Toronto, Ontario; 10 October 2013.
118. AstraZeneca Canada Inc. IMFINZI® product monograph. Mississauga, Ontario; 4 May 2018.
119. Novopharm. Epirubicin for Injection product monograph. Toronto, Ontario; 16 March 2009.
120. Pharmaceutical Partners of Canada, Inc. Epirubicin Hydrochloride Injection product monograph. Richmond Hill, Ontario; 6 July 2010.
121. Pharmacia Canada Inc. Pharmorubicin PFS Package Insert. Mississauga, Ontario; May 2003.
122. Trissel LA. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2003.
123. BC Cancer Agency Lymphoma Tumour Group. (ULYEPOCHR) Interim BCCA Protocol Summary for Treatment of Lymphoma with Dose-Adjusted Etoposide, DOXOrubicin,
VinCRIStine, Cyclophosphamide, PredniSONE, and riTUXimab (LYEPOCHR) with Intrathecal Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 1 July 2015.
124. Barry Goldspiel. Personal communication. NIH Clinical Centre; 14 April 2015.
125. Wolfe JL, Thoma LA, Du C, et al. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. Am J Health-Syst
Pharm 1999;56:985-989.
126. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 2013;369:1915-1925.
127. Eisai Limited. HALAVEN® product monograph. Mississauga, Ontario; 17 January 2013.
128. Sandoz Canada Inc. Etoposide injection® product monograph. Kirkland, Quebec; 27 February 2012.
129. BC Cancer Agency. Provincial Pharmacy Directive III-50-04: Management of Particulate During Sterile Preparation. Vancouver, British Columbia: BC Cancer Agency; 9 July
2014.
130. Novopharm Limited. Etoposide Product Monograph. Toronto, Ontario; 2000.

131. Lepage R, Walker S, Godin J. Stability and compatibility of etoposide in normal saline. Canadian Journal of Hospital Pharmacy 2000;53(5):338-345.
132. The United States Pharmacopeial Convention, Inc. General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United
States Pharmacopeial Convention, Inc.; 2003.
133. Angie Chan. Personal communication. Drug Information Pharmacist, Novopharm. 29 September 2006.
134. Bristol-Myers Squibb Company. ETOPOPHOS® product monograph. Princeton, New Jersey, USA; March 2011.
135. Bristol-Myers Squibb Company. ETOPOPHOS® product monograph. Princeton, New Jersey, USA; September 2013.
136. Amgen Canada Inc. NEUPOGEN® product monograph. MIssissauga, Ontario; 21 March 2014.
137. Amgen Medical Information. Personal communication. Amgen Canada Inc.; 8 July 2014.
138. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2005. p. 648-655.
139. Berlex Canada Inc. Fludara Package Insert. Lachine, Quebec; December 1998.
140. Trissel's™2 Clinical Pharmaceutics Database (Parenteral Compatibility) [database on the internet]. Fludarabine. Thomson MICROMEDEX®, Available at:
http://www.micromedex.com/. Accessed 14 September, 2007.
141. Novopharm Limited. Fludarabine product information package. Toronto, Ontario; 21 June 2007.
142. Accord Healthcare Inc. Fluorouracil injection® product monograph. Kirkland, Quebec; 30 September 2013.
143. Charles Vachon. Personal communication. Quality and Regulatory Affairs, Accord Healthcare Inc.; 29 September 2016.
144. John Korontzis. Personal communication. Regulatory Affairs Associate, Fluorouracil, Mayne Pharma Canada; reference # FEB-43-2005.February 16, 2005.
145. Pfizer Canada Inc. Fluorouracil injection product monograph. Kirkland, Quebec; 17 April 2018.
146. Trissel LA. Fluorouracil. Handbook on Injectable Drugs: 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2005. p. 672-681.
147. Stiles ML, Allen Jr LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. American Journal of Hospital Pharmacy 1989;46(10):2036-2040.
148. BC Cancer Agency Experimental Therapeutics. Physicochemical stability analysis of fluorouracil products in final chemotherapeutic preparations.Vancouver, BC. 19 August
2011;Study number 50009:1-43.
149. Sandoz Canada Inc. Fluorouracil Injection product monograph. Boucherville, Quebec; 3 April 2012.
150. Alexandre Dussault. Personal communication. Drug Information & Pharmacovigilance Coordinator, Sandoz Canada Inc.; 19 November 2015.
151. Accord Healthcare Inc. Gemcitabine injection® product monograph. Kirkland, Quebec; 29 September 2014.
152. Astron Research LTD. UK. Gemcitabine for Injection (STBRG/ACGEM/01) Stability Study Report (Dilution Study) 2001.
153. Purvi Agrawal BPharm (Regulatory Affairs Manager). Personal communication. Accord Healthcare Inc.; 07 September 2012.
154. Pfizer Canada Inc. Gemcitabine Injection (ready to use solution) product monograph. Kirkland, Quebec; 25 October 2018.
155. Pfizer Canada Inc. Gemcitabine Injection (ready to use solution) product monograph. Kirkland, Quebec; 24 August 2017.
156. Sandoz Canada Inc. Gemcitabine hydrochloride solution for injection product monograph. Boucherville, Quebec; 14 August 2014.
157. Pfizer Canada Inc. IDAMYCIN® product monograph. Kirkland, Quebec; 19 February 2009.
158. Pharmaceutical Partners of Canada, Inc. IDARUBICIN HYDROCHLORIDE INJECTION® product monograph. Richmond Hill, Ontario; 12 November 2009.
159. Baxter Corporation. IFEX® product monograph. Mississauga, Ontario; 5 April 2012.
160. Pharmaceutical Partners of Canada, Inc. Ifosfamide for Injection product monograph. Richmond Hill, Ontario; 17 January 2008.
161. sanofi-aventis Canada. Iniparib (BSI-201;SAR240550) Special Access Program Guidance for the Physician. Laval, Quebec; 15December2010.
162. Pfizer Canada Inc. BESPONSA® product monograph. Kirkland, Quebec; 15 March 2018.
163. Pfizer Canada Inc. Personal communication. Pfizer Canada Medical Information; 26 November 2018.
164. Merck Canada Inc. INTRON A® product monograph. Kirkland, Quebec; 13 March 2015.
165. Edward Kavalec BSc(Pharm), Medical Services Specialist. Personal communication. Merck Canada Inc. Medical Information; 1 April 2015.
166. Bristol Myers Squibb Canada. YERVOY® product monograph. Montreal, Quebec; 1 February 2012.
167. Accord Healthcare Inc. Irinotecan injection® product monograph. Kirkland, Quebec; 6 May 2014.
168. Pfizer Canada Inc. Irinotecan hydrochloride trihydrate for injection product monograph. Kirkland, Quebec; 6 March 2019.
169. Pfizer Canada Inc. Irinotecan hydrochloride injection product monograph. Kirkland, Quebec; 8 March 2019.
170. Servier Canada Inc. ONIVYDE® product monograph. Laval, Quebec; 4 January 2019.
171. Bristol-Myers Squibb. IXEMPRA® product monograph. Princeton, New Jersey; 01 October 2007.
172. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5.


Chemo Stability Chart - AtoK PDF

Uploaded by

Copyright:

Available Formats

You might also like

Chemo Stability Chart - AtoK PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Chemo Stability Chart - AtoK PDF

Uploaded by

Copyright:

Available Formats

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 1/49

transfer 1.5mL from

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 2/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 3/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 4/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 5/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 6/49

record time of if a closed system

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 7/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 8/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 9/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 10/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 11/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 12/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 13/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 14/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 15/49

swirl gently; do NOT

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 16/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 17/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 18/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 19/49

do NOT use D5W

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 20/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 21/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 22/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 23/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 24/49

swirl gently; avoid

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 25/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 26/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 27/49

Let sit for 5

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 28/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 29/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 30/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 31/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 32/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 33/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 34/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 35/49

(e.g., 50-1000 mL*

CIVI: ambulatory complete within 8

(e.g., 50-1000 mL*

CIVI: ambulatory complete within

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 36/49

CIVI: ambulatory complete within

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 37/49

vial contents under

do NOT use BWI to

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 38/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 39/49

Interferon Alfa -2b

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 40/49

Interferon Alfa -2b

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 41/49

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00 42/49